| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992519 | Journal of Thoracic Oncology | 2006 | 5 Pages |
Abstract
The MTD of this combination was amrubicin 40 mg/m2 and carboplatin AUC 4.0, and the recommended dose for a phase II trial is a combination of amrubicin 35 mg/m2 and carboplatin AUC 4.0. We are now conducting a multicenter phase II trial of this regimen to determine the activity of this combination for elderly patients with SCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Akira MD, Koichi MD, Makoto MD, Takuji MD, Yuichiro MD, Mariko MD, Hiroshi MD, Masaharu MD, Yasuo MD, Toshihiro MD,